

## 7. The References

1. Alan S, K, Journal of Renal Nutrition July Vol. 12 No 3. (2002).
2. Avram; M.M; Predictions of survival in continous ambulatory pritoneal dialysis patients: AM.J.Kidney Dis. 23: 1994.
3. Barany, P; Divino. J. C; Bergstrom, J., High C-reactue protein in haemodialysis patients. Am .J. Kidney Dis, 29: 565 – 568 (1997).
4. Bayne, J; Marek H.D; Medical Biochemistry, Mosby publishing Co. pp 22 – 24 (1999).
5. Berner, L. M: the kidney “physiology” pp 928. (1983).
6. Bologa, R.M; Levine, D.M; Parker, T.S; in terleukin – 6 – predicts hypoalbumiraemia, hypocholesterolemia and mortality in hemodialysis patients, Am.J.Kidney Dis. 23;107 – 114 (1998).
7. Carl A.B; Eaward R,T Fundamentals of clinical chemistry 5<sup>th</sup> ed. W.D. Saundeers company pp 329 (2001).
8. Clanciaruso, B,Braunori, G, Kopple, J.D. Traverso, G; cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and haemodialysis patients. A.M.J. kindeny Dis, 26: 475-86,1995.
9. Collier, L, Oxford, J; Human virology ; A text for Students of Medicine, Dentistry, and Micro oxford, Newyork, Tokyo, Oxford, Univ. press (1993).
10. Cueto MAM. Rev. invest. Clin 53 (2): 152 – 58, (2001).
11. Danish, MMI: Shart textbook of Medical diagnosis and Management, Second. (1997).
12. Don BR, Kaysan GA, Journal of Renal Nephrology, 13: 249 – 59, (2000).

13. Edward, CR, Bouchier IA, Haslett C, Chilvers E: Disease of the kidney and geneto – urinary system, “Davison” principle practice of medicine 17<sup>th</sup> ed. London ELBS pp 612 – 52.(1986).
14. Eschloach, A.A, Website: [http://www. nephrology. Rei. Edu/MICS 03. htm](http://www.nephrology.Rei.Edu/MICS%2003.htm) . (1994). Tam, A.S. Gones.C. Lone: T. Webster.
15. Foley RN, Perfrey PS, hamet JD, Kent GM, Murry DC, barre PE, J. Am. Sce. Nephrol. May; 7 (5) 728 – 36 (1996). Epidemiology of cardio vascular disease in CRD.
16. Gangong, W.F; of Medical Physiology, 16<sup>th</sup> ed. Appleton & Lange PP 635 – 39. (1993).
17. George, A, Kaysen, M.D; Why measure serum albumin levels, J. of Penal Nutrition, Volume, 12, July,(2002).
18. Graig T.C; Wilcox C; Nephrology 3<sup>rd</sup> ed. New York: Mass publishing Company PP 112 – 125, (1995).
19. Gunnell, J; Yeun. J.Y., Depner, TA, Kaysen, GA, Acute phase response predects erythropietin resitance in haemodialysis and peritoneal dialysis patients, Am. J. Kidney Dis. 33: 63 – 72 (1999).
20. Hakim, R.M; and levin, N,: Nutrition in haemodialysis patients. Am. J. kidney Dis: 21: 125 – 137 (1993).
21. Ikizler, TA, Wingard, RL, Harvell, J; Shyr, A.A, Association of marbidity with markers of nutrition and inflammation in chronic haemodialysis patients kidney inst; 55: 1945 – 11951, (1999).
22. Iseki, K; Tozaua, M; Yoshi, S; Fukiyama, K; serum C- erative protein and risk of death in chronic dialysis patients. Nephrol Dial, Transplant, M: (1956 – 1960 – 1999).

23. Jermy levy, J.M., Edwin B. Oxford handbooks of dialysis, Oxford University press (2001).
24. Jon B; Marek HD., Medical Biochemistry, Mosby publishing Co. PP 22 –24 (1999).
25. Jones, C.H., Colin, A.A; Jerome albumin and survival in CAPD patients. The implication of concentration Trend over time. Nephrology dialysis transept.12 (3) 554 – 8 (1997).
26. Jones, C.H; Can a reduction in extra cellular fluid volume result in the increased serum albumin in peritoneal dialysis patients. Am. J. K. Dis; 39 (4), 872 – 5 (2002).
27. Johanson, A; Samvelesson, O; Haraldson, B; Bosaeus,J; Body composition in patients Treated with peritoneal dialysis, Nephrol Dial. Transplant, B: 1511 – 17 (1998).
28. Kagan, A, Bar, K.Y; Role of peritoneal loss of albumin in the hypoalbuminaemia of continuos ambulatory PD patients. Nephron, 71: 314 – 20 (1995).
- 29- Kalanter, K.Z., Malnutrition-inflammation complex syndrome in dialysis patients. Causes and consequences, American journal of kidney disesae. V. 42,November 5(2003).
- 30- Kalanter, Z.K., McA Lliter, C; Lehn, G. Kapplen J; Effects of malnutrition – inflammation complex syndrome on EPO hyporesponse ness in maintenance haemodialysis patients. Am. J. Kidney Dis; 42: 761 – 773, (2003).

- 31- Kalpan, L; J Pesce: A clinical Chemistry theory, analysis and correlation, 2th ed. The CV mosby Company pp 325 – 54, (1989).
- 32- Kamyar K, Zadeh, T. Alp Ikizler, Gladys B; Morrel M. Avaram, Joel D. Kopple: American Journal of kidney diseases Nov. Vol 42 No 5, (2003).
- 33- Kasan GA: Minerals; Electrolytes Metab. 24 91); pp 55 – 63, (1998).
- 34- Kaysen, GA, Rathore, V; Shearer, GC., Mechanism of hypoalbuminaemia in haemodialysis patients, Kidney int, 48 : 510 – 16, (1995).
- 35- Kaysen GA, Levin NW, Journal of Renal Nutrition July Vol. 12 No 3. (2002).
- 36- Kaysen, G.A; Stevenson, F.T, Deppner, T.A, Determination of albumin concentration in haemodialysis patients, Am. J. Kidney Dis, 29: 658 – 668 (1997).
- 37- Kliger, A.S, Alan, S; Servun albumin measurement in dialysis patients: should it be a measure of clinical performance. J. of Renal Nutrition, Volume 12, November3 (2002).
- 38- Kopple, JD: Pathophysiology of protein – energy wasting in CRF J. Nut. 129: 247 – 51, (1999).
- 39- Kramer, G. C, Sibley, L; Aukland, K; Sampling of intestinal fluid in rat skin, further analysis and modifications of the method, microvasc. Res 32: 39 – 49, (1986).
- 40- Kumar, P; Clark, M; Clinical Medicine, Textbook for medical students and doctors, 3 rd Edition, (1999).

- 41- Laker, M. F. Clinical Biochemistry for Medical students, W. B. Saunders Company LTd, (1996).
- 42- Lowie, C.C; porl, F.K; WALF< R.A; Disparities incidence of diabetic end-stage renal disease according to race and type of diabetes; England J of Med.321, 1074-1074.(1989).
- 43- Mahendra A; Acute Renal Failure, Emedicine, July 12, (2002).
- 44- Makkmann, p; Nutritional status of patients on haemodialysis and peritoneal dialysis, clin, Nephrol, 29:75-78,1988.
- 45- Marshal, W.J Clinical Chemistry, 3<sup>th</sup> ed.
- 46- Mauro V: Chronic Renal Failure, Emedicine, Jan 20, (2004).
- 47- Mayne P.D; Clinical Chemistry in diagnosis and treatment, Edward Arnold, p3 (1994).
- 48- Michael, C; M; EL. Tigani, A, Khalid, I. O; Hyams, K; Hepatitis Band Cin Juba, Southern Sudan: results of a serosurvey Trans. Royal soc. Trop Med and Hyg. 88, 534 – 536, (1994).
- 49- Miller, Jones, R.J. Piantadosi, S, Abeloff, M. D; Decreased erythropoietin response in patients with the anaemia of concer, N. Engl . J. Med. Inst 56: 758 – 759, (1990).
- 50- Mogensium, A. S; Christensen, S.A; Kideny and urinary tract Muirs textbook of pathology; 13ed, London, Elbs,(1984).
- 51- National Kidney Foundation: K/DOQI Clinical practice Guidelines for Nutrition in chronic renal failure. New York, NY, Nutritional kidney Foundation, (2000).

- 52- Qureshi, A.R; Alvestrand, A, Danie Isson, A factors predicting malnutrition in haemodialysis patients; A cross-sectional study kidney inst. 1998, 53: 773-782.
- 53- Raine, A.E; the rising tide of diabetic nephropathy, the warning before the food, Nephrol Dial Transport 10,460-461, (1995).
- 54- Schooly, J.C; Kullgren, B; Allison, A. C; inhibition by interleukin -1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of the anaemia of chronic disease. Blood, 80 : 1639 – 1647, (1987).
- 55- Sezer S, Ozdemir FN, Akman B, Arat Z, Anaforoglu I, Haberal M, Adv. Perit. Dial 17; 210 – 4 (2001).
- 56- Soejima, A; Matsuawa, N, Miyake, A.B.; Hypoalbuminaemia accelerates erythrocyte membrane lipid peroxidation in chronic haemodialysis patients clin Nephrol, V.51:92-97(1999).
- 57- Stenvinkel, P., Alvestrand, A, inflammation in end – stage renal disease, consequences, and therapy. Semin Dial, 15: 329 – 337, (2002).
- 58- Stenvinkel, P. the role of inflammation in the anaemia of ESRD Nephrol. Dial. transplant, 16: 536 – 540, (2001).
- 59- Stenvinkel, P; Andersson, P; Wang, T; Do ACE – inhibitors suppress tumour necrosis factor –  $\alpha$  – production in advanced chronic renal failure. J. intern. Med. 246 – 507, (1999).
- 60- Steinman TI. Semin. Dialysis Nov; 13 (6) 404 – 8, (2000).
- 61- Suliman, S. M; Fessaha, S; Elsading, M., Elhadi, M. B, Lombert, S; Presentation of hepatitis C virus infection in

- haemodialysis patients in Sudan, Saudi J. Kidney Dis. Transplant, 6: 154 – 156, (1995).
- 62- Techan, B. P; Urea Kinetic analysis and clinical outcome on CAPD. A five year longitudinal study; Adv. In peritoneal analysis, 6: 181 – 5, (1990).
- 63- Timbury, M; C; Notes on medical virology, Eighth Ed. Churchill livingstone, Edinburgh London, (1986).
- 64- Thunberg, BJ, Alogiri, P.S., Cestero, R. V.; Cross – Sectional and longitudinal nutritional assessment in maintenance haemodialysis patients. Am. Jclin Nutr, 34: 2005 – 112, (1981).
- 65- Verrelli: M., Chronic renal failure, Emedicine, Jan 20, (2004).
- 66- Voulgari, P. V; Kolios, G, Popadopoulos, G. K, Drosos, A. A; Role of cytokines in the pathogenesis of anaemia of chronic disease in rheumatoid arthritis: Clin – immunol. 92: 153 – 160, (1999).
- 67- Zimmermann, J, Herrlinger; S, pruy, A, Metzger, J, wanner, c; inflammation enhances cardiovascular risk and mortality in haemodialysis patients, kidney inst; 55:648-658; 1999.

## **Abstracts**

This study was carried out with the participation of 60 patients with end stage renal disease (ESRD). 30 patients were seen at Khartoum Center of Dialysis and Transplantation in which were under haemodialysis therapy, and other 30 patients were seen at Military Hospital, Omdurman in which they were under peritoneal dialysis. The two groups of end – stage renal disease were nearly matched in age and sex.

Albumin concentration in each group was measured following either renal dialysis in order to assess the adverse effect and to assess impact of each dialysis method on the concentration of serum albumin.

Preliminary investigation revealed that the majority of ESRD patients in each group were presented with other disease namely hypertension, diabetes mellitus and also infection of Hepatitis virus (HBV) were found in about 26% of ESRD patients under haemodialysis and about 7% of ESRD patients under peritoneal dialysis.

The findings of this study also showed that all patients of ESRD of each group maintained low serum albumin concentration pre – dialysis (below albumin reference value) and the level markedly decreased postdialysis with varying degree, the most serum albumin decrease was found in ESRD patients under peritoneal dialysis. Males exhibit more reduction in albumin concentration than females in peritoneal dialysis while in haemodialysis, no statistical differences of albumin concentration were found between males and

females. Similarly, peritoneal dialysis has shown sever and more reduction of albumin concentration in ESRD patients over 50 year of age than ESRD patients over 50 years of age, while under haemodialysis the age appeared to has not effect on the level of albumin concentration.

The explanation of reduced serum albumin under renal dialysis was reported to be due to malnutrition, inflammation and persistent fluid overload. And it is presumed that malnutrition with low serum albumin is powerful predictor of mortality in ESRD patients. It is also believed that fall in serum albumin level in ESRD patients during renal dialysis is assciated with the progression of development of cardiac failure and overall mortality and hyperalbuminaemia is considered a major adverse prognostic factor in dialysis patients, is ctrongly associated with cardiac disease.

## **Abbreviation**

|       |   |                                            |
|-------|---|--------------------------------------------|
| ESRD  | : | End. Stage renal disease.                  |
| JGA   | : | Juxtaglomerular apparatus.                 |
| MD    | : | Maintenance dialysis.                      |
| GFR   | : | Glomerular filtration rate.                |
| AKI   | : | Acute renal failure.                       |
| BUN   | : | Blood urea nitrogen.                       |
| ACE   | : | Angiotensin – converting enzyme.           |
| NSAID | : | Nonsteroidal anti – inflammatory drugs.    |
| ANCA  | : | Antineutrophil cytoplasmic antibodies.     |
| FENa  | : | Fractional excretion of sodium.            |
| CRF   | : | Chronic renal failure.                     |
| PTH   | : | Parathyroid hormone.                       |
| TTP   | : | Thrombotic thrombocytopenic purpura.       |
| HIV   | : | Human immunodeficiency virus.              |
| HUS   | : | Hemolytic – uremic syndrome.               |
| ANA   | : | Antinuclear antibodies.                    |
| CAPD  | : | Continuous ambulatory peritoneal dialysis. |
| IPD   | : | Intermittent peritoneal dialysis.          |
| HD    | : | Haemodialysis.                             |
| PD    | : | Peritoneal dialysis.                       |
| ATN   | : | Acute tubular necrosis.                    |

## Table of contents

| Description |                              | Page |
|-------------|------------------------------|------|
|             | Dedication .....             | i    |
|             | Declaration .....            | ii   |
|             | Acknowledgment .....         | iii  |
|             | Abstract                     | iv   |
|             | ملخص البحث.....              | v    |
|             | Abbreviation .....           | vi   |
|             | List of tables .....         | vii  |
|             | List of figures .....        | viii |
|             | <b>Chapter one</b>           |      |
| 1.          | Introduction .....           | 1    |
|             | <b>Chapter two</b>           |      |
| 2.          | Literature Review .....      | 3    |
| 2.1.        | The kidney .....             | 3    |
| 2.2.1.      | Structure and anatomy .....  | 3    |
| 2.1.2.      | Function of the kidney ..... | 4    |
| 2.1.3.      | Acute Renal Failure<br>..... | 5    |
| 2.1.3.1.    | Pathophysiology.....         | 6    |
| 2.1.3.2.    | Intrinsic renal failure..... | 7    |
| 2.1.3.3.    | Frequency.....               | 9    |
| 2.1.3.4.    | Causes .....                 | 10   |
| 2.1.3.5.    | Lab. studies .....           | 12   |
| 2.1.3.6.    | Diet .....                   | 15   |
| 2.1.4.      | Chronic renal failure .....  | 16   |
| 2.1.4.1.    | Pathophysiology .....        | 16   |
| 2.1.4.2.    | History .....                | 17   |
| 2.1.4.3.    | Causes .....                 | 20   |
| 2.1.4.4.    | Lab. Studies .....           | 22   |
| 2.1.4.5.    | Diet .....                   | 23   |

|        |                                               |             |
|--------|-----------------------------------------------|-------------|
| 2.2.   | Dialysis . . . . .                            | 24          |
|        | <b>Description</b>                            | <b>Page</b> |
| 1.2.1. | Principle of haemodialysis . . . . .          | 25          |
| 1.2.2. | Ultrafiltration . . . . .                     | 26          |
| 1.2.3. | Dialysers . . . . .                           | 26          |
| 1.2.4. | Dialysate . . . . .                           | 27          |
| 1.2.5. | Laboratory tests . . . . .                    | 28          |
| 1.2.6. | Principle of peritoneal dialysis . . . . .    | 29          |
| 1.2.7. | Models of peritoneal dialysis . . . . .       | 30          |
| 1.2.8. | CAPO Technique and dialysis . . . . .         | 31          |
| 1.2.9. | Adequacy of peritoneal dialysis . . . . .     | 33          |
| 2.3.   | Malnutrition in ESRD . . . . .                | 35          |
| 2.4.   | Nutritional requirement in CRF . . . . .      | 36          |
| 2.5.   | Albumin . . . . .                             | 37          |
| 2.5.1. | Hypoalbuminaemia in dialysis . . . . .        | 38          |
| 2.5.2. | Objective . . . . .                           | 42          |
|        | <b>Chapter three</b>                          |             |
| 3.     | Materials and methods . . . . .               | 43          |
| 3.1.   | Materials . . . . .                           | 43          |
| 3.1.1. | Patients . . . . .                            | 43          |
| 3.1.2. | Sample collection and processing . . . . .    | 43          |
| 3.1.3. | Analytical method used in the study . . . . . | 43          |
| 3.2.   | Methods . . . . .                             | 44          |
| 3.2.1. | Estimation of serum albumin . . . . .         | 44          |
| 3.2.2. | Analysis of data . . . . .                    | 45          |
|        | <b>Chapter four</b>                           |             |
| 4.     | Results . . . . .                             | 46          |
|        | <b>Chapter five</b>                           |             |
| 5.     | Discussion . . . . .                          | 57          |
|        | <b>Chapter six</b>                            |             |
| 6.     | Conclusion and recommendation . . . . .       | 70          |
|        | <b>Chapter seven</b>                          |             |

|    |                  |    |
|----|------------------|----|
| 7. | References ..... | 72 |
|----|------------------|----|

## List of table

| <b>Table</b> | <b>Description</b>                                                                 | <b>Page</b> |
|--------------|------------------------------------------------------------------------------------|-------------|
| 1.           | Figure (A): general structure of the kidney.                                       | -           |
| 2.           | Figure (B): the nephron.                                                           | -           |
| 3.           | Figure (D): peritoneal dialysis.                                                   | -           |
| 4.           | Figure (E): dialysis and dialysate.                                                | -           |
| 5.           | Figure (F): hemodialysis.                                                          | -           |
| 6.           | Mean Age of Renal diseased patients under Renal dialysis                           | 48          |
| 7.           | Percentage of sex Distribution in ESRD patients                                    | 49          |
| 8.           | Disease History in Renal –diseased patients                                        | 50          |
| 9.           | Mean Albumin conc. in ESRD patients under peritoneal dialysis.                     | 51          |
| 10.          | Mean Albumin Conc. in ESRD patients under Haemodialysis                            | 52          |
| 11.          | Mean Albumin Conc. In males and females of ESRD patients under peritoneal dialysis | 53          |
| 12.          | Mean Albumin Conc. In males and females is ESRD patients under Haemodialysis       | 54          |
| 13.          | Mean Albumin Conc. According to age groups in ESRD patients under Haemodialysis    | 55          |
| 14.          | Mean Albumin Conc. According to age in ESRD patients under peritoneal dialysis     | 56          |

## List of figures

| <b>Table</b> | <b>Description</b>                                                                 | <b>Page</b> |
|--------------|------------------------------------------------------------------------------------|-------------|
| 1.           | Mean Age of Renal diseased patients under Renal dialysis                           | 48          |
| 2.           | Percentage of sex Distribution in ESRD patients                                    | 49          |
| 3.           | Disease History in Renal –diseased patients                                        | 50          |
| 4.           | Mean Albumin conc. in ESRD patients under peritoneal dialysis                      | 51          |
| 5.           | Mean Albumin Conc. in ESRD patients under Haemodialysis                            | 52          |
| 6.           | Mean Albumin Conc. In males and females of ESRD patients under peritoneal dialysis | 53          |
| 7.           | Mean Albumin Conc. In males and females is ESRD patients under Haemodialysis       | 54          |
| 8.           | Mean Albumin Conc. According to age groups in ESRD patients under Haemodialysis    | 55          |
| 9.           | Mean Albumin Conc. According to age in ESRD patients under peritoneal dialysis     | 56          |

أُجريت هذه الدراسة علي 60 مريضاً من مرضي الفشل الكلوي المتأخر والذين تحت العلاج بالغسيل الدموي (30 مريضاً) و تحت الغسيل البريتوني (30 مريضاً) حيث تمت مقابلة المرضى في مركز الخرطوم لغسيل وزراعة الكلي (حيث يجري الغسيل الدموي) والمستشفى العسكري بأمدرمان (حيث يجري الغسيل البريتوني).

تم قياس تركيز الالبومين في سيريوم كل المرضى من المجموعتين قبل وبعد إجراء الغسيل الكلوي بنوعيه وذلك لدراسة تأثير الغسيل الكلوي علي مستوى تركيز الالبومين ومعرفة العوامل التي تسبب أو تؤثر علي هذا المستوى.

أوضحت الفحوصات الأولية للمرضي في كلا المجموعتين أن غالبية المرضى يعانون من أمراض أخرى مصاحبه لمرض الكلي لديهم مثل ارتفاع ضغط الدم ومرض السكري وأيضاً وجود إصابات بالتهاب الكبد الفيروسي (HBV) في حوالي 20% من المرضى الذين يتعالجون بالغسيل الدموي و حوالي 7% من المرضى الذين تحت الغسيل البريتوني.

أوضحت نتائج الدراسة أن مستوى تركيز الالبومين لدي المرضى الذين تحت الغسيل البريتوني أو الغسيل الدموي كان أقل من مستوى تركيز الالبومين في الحالات السوية حتى قبل إجراء الغسيل الكلوي ، وأن هناك انخفاضاً معنوياً في تركيز الالبومين بعد الغسيل البريتوني أكثر منه في حالة الغسيل الدموي.

كما أوضحت الدراسة أن مستوى انخفاض الالبومين كان أكثر لدي الذكور مقارنة بالإناث وذلك في حالة الغسيل البريتوني ، أما في حالة الغسيل الدموي فلا يوجد فرقاً معنوياً في مستوى تركيز الالبومين بين الذكور والإناث.

أما عند دراسة تأثير العمر علي مستوى تركيز الالبومين في حالة الغسيل الكلوي بنوعيه ، أتضح أن المرضى الذين تزيد أعمارهم من 50 سنة أكثر عرضه لانخفاض مستوى تركيز الالبومين مقارنة بالمرضى الذين تقل أعمارهم عن 50 عاماً وذلك في حالة الغسيل البريتوني ، أما في حالة الغسيل الدموي فلا يوجد فرقاً معنوياً في تركيز الالبومين في المرضى من كل الأعمار.

ناقشة الدراسة أيضاً أسباب انخفاض الالبومين لدي مرضي الفشل الكلوي حيث تشير التفسيرات من قبل الباحثين إلي دور سوء التغذية ونقص الغذاء والحالات الالتهابية من الأسباب الرئيسية لانخفاض تركيز الالبومين هذا إلي جانب زيادة تركيز سوائل الجسم الأخرى . وأن الالبومين يمكن اعتباره من المؤشرات القوية لحدوث حالات إصابات الأوعية الدموية والوفاة لكثير من مرضي الفشل الكلوي.